PP
PRTK

Paloma Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Paloma Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-34,890
Closed -$876K – 2396
2017
Q3 		$876K Sell
34,890
-1,093
-3% -$25.4K 0.01% 1223
2017
Q2 		$867K Buy
+35,983
New +$795K 0.01% 1273
2013
Q3 		– Sell
-4,564
Closed -$165K – 1247
2013
Q2 		$165K Buy
+4,564
New +$196K 0.01% 997

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Paloma Partners's PRTK Position: Q4 2017 in Review

Paloma Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 34,890 shares — an estimated $876K sold.

Paloma Partners first reported a position in PRTK in Q2 2013 and held it in 3 quarters. The position peaked at $876K in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Paloma Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Paloma Partners sold 34,890 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $876K.
  • Paloma Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • Paloma Partners's Paratek Pharmaceuticals, Inc. position peaked at $876K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Paloma Partners's 13F filing for Q4 2017, filed 14 Feb 2018.